Eran Ophir Sells 5,000 Shares of Compugen (NASDAQ:CGEN) Stock

Compugen Ltd. (NASDAQ:CGEN) CEO Eran Ophir sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $2.90, for a total value of $14,500.00. Following the sale, the chief executive officer directly owned 11,375 shares of the company’s stock, valued at $32,987.50. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eran Ophir also recently made the following trade(s):

• On Wednesday, April 1st, Eran Ophir sold 5,625 shares of Compugen stock. The stock was sold at an average price of $2.21, for a total value of $12,431.25.

Compugen Price Performance

CGEN opened at $2.89 on Friday. Compugen Ltd. has a fifty-two week low of $1.23 and a fifty-two week high of $2.94. The business has a 50-day moving average of $2.09 and a 200-day moving average of $1.85. The company has a market capitalization of $273.25 million, a PE ratio of 7.81 and a beta of 2.77.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings results on Monday, March 2nd. The biotechnology company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.55. Compugen had a return on equity of 55.68% and a net margin of 48.57%.The company had revenue of $67.33 million during the quarter, compared to the consensus estimate of $14.30 million. On average, equities research analysts expect that Compugen Ltd. will post -0.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Lake Street Capital assumed coverage on Compugen in a research note on Tuesday, April 7th. They set a “buy” rating and a $6.00 price target for the company. Truist Financial raised Compugen to a “strong-buy” rating in a research note on Wednesday, March 25th. Wall Street Zen raised Compugen from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compugen in a research note on Wednesday, January 21st. Finally, HC Wainwright initiated coverage on Compugen in a report on Wednesday, January 7th. They set a “buy” rating and a $4.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Compugen currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.00.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC increased its position in Compugen by 3.7% in the 4th quarter. Renaissance Technologies LLC now owns 1,456,900 shares of the biotechnology company’s stock worth $2,229,000 after buying an additional 51,565 shares during the period. State Street Corp increased its position in Compugen by 3.9% in the 4th quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock worth $603,000 after buying an additional 14,701 shares during the period. Jane Street Group LLC increased its position in Compugen by 1,077.0% in the 2nd quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock worth $700,000 after buying an additional 359,785 shares during the period. Two Sigma Investments LP increased its position in Compugen by 10.6% in the 3rd quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock worth $291,000 after buying an additional 18,929 shares during the period. Finally, Marshall Wace LLP increased its position in Compugen by 135.7% in the 4th quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock worth $163,000 after buying an additional 61,202 shares during the period. 12.22% of the stock is owned by institutional investors.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.